Use of low free to total PSA ratio in prostate cancer screening: Detection rates, clinical and pathological findings in Brazilian men with serum PSA levels < 4.0 ng/mL

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Faria, Eliney Ferreira ^a   Carvalhal, Gustavo F ^a   Dos Reis, Rodolfo Borges ^a   Tobias Machado, Marcos ^a   Vieira, Renê A C ^a   Reis, Leonardo O ^a   Nogueira, Lucas ^a   MacHado, Roberto Dias ^a   Freitas Jr , Celso H ^a   Magnabosco, Wesley J ^a   Mauad, Edmundo C ^a   Carvalho, André Lopes ^a  

^a Cancer Hospital of Barretos   (Brazil)

Author keywords

Prostate cancer; Prostate specific antigen; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BRAZILIAN; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; ETHNIC GROUP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; BLOOD; BRAZIL; COMPARATIVE STUDY; EARLY DIAGNOSIS; FOLLOW UP; INCIDENCE; MASS SCREENING; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; STATISTICS;

BRAZIL; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

MLCS; MLOWN;

EID: 84876446018     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11398.x     Document Type: Article

References (18)

1. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996 ; 276 : 1309-15
2. Schroder FH, Hugosson J, Roobol MJ et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009 ; 360 : 1320-8
3. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostatecancer screening trial. Lancet Oncol 2010 ; 11 : 725-32
4. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997 ; 277 : 1452-5
5. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998 ; 159 : 5-12
6. Thompson IM, Ankerst DP, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol 2008 ; 180 : 1219-22
7. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000 ; 163 : 806-12
8. Makinen T, Tammela TL, Hakama M et al. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./mL.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 2001 ; 166 : 1339-42
9. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000 ; 56 : 255-60
10. Faria EF, Carvalhal GF, Vieira RA, Silva TB, Mauad EC, Carvalho AL. Program for prostate cancer screening using a mobile unit: results from Brazil. Urology 2010 ; 76 : 1052-7
11. Faria EF, Carvalhal GF, Vieira RA et al. Comparison of clinical and pathologic findings of prostate cancers detected through screening versus conventional referral in Brazil. Clin Genitourin Cancer 2011 ; 9 : 104-8
12. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005 ; 29 : 1228-42
13. Catalona WJ, Loeb S. Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw 2010 ; 8 : 265-70
14. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./mL. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./mL. range. J Urol 2002 ; 168 : 504-8
15. Tornblom M, Norming U, Adolfsson J et al. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology 1999 ; 53 : 945-50
16. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 ; 279 : 1542-7
17. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006 ; 98 : 529-34
18. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001 ; 58 : 843-8